884. Patient Adherence to Long-Acting Injectable Cabotegravir + Rilpivirine Through 48 Weeks of Maintenance Therapy in the Phase 3 ATLAS and FLAIR Studies

Lignende værker

• Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks
  af: Murray, Miranda, et al.
  Udgivet: (2020)
• Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials
  af: Rizzardini, Giuliano, et al.
  Udgivet: (2020)
• 1029. Long-Term Patient Adherence and Management of Treatment Interruptions With Long-Acting Injectable Cabotegravir + Rilpivirine for Maintenance Therapy in Phase IIb/III Studies
  af: Teichner, Paula, et al.
  Udgivet: (2020)
• 1035. Patient-Reported Outcomes on Long-Acting Cabotegravir + Rilpivirine as Maintenance Therapy: FLAIR 96-Week Results
  af: Chounta, Vasiliki, et al.
  Udgivet: (2020)
• The 96-week outcomes and pharmacokinetics of long-acting cabotegravir plus rilpivirine in South Africans
  af: Rosie Mngqibisa, et al.
  Udgivet: (2025-07-01)